

# Daniel E Spratt

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5254719/publications.pdf>

Version: 2024-02-01

334  
papers

13,405  
citations

31902

53  
h-index

31759

101  
g-index

338  
all docs

338  
docs citations

338  
times ranked

15091  
citing authors

#	ARTICLE	IF	CITATIONS
1	Integrating Prostate-specific Antigen Kinetics into Contemporary Predictive Nomograms of Salvage Radiotherapy After Radical Prostatectomy. <i>European Urology Oncology</i> , 2022, 5, 304-313.	2.6	12
2	Impact of Decipher Biopsy testing on clinical outcomes in localized prostate cancer in a prospective statewide collaborative. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 677-683.	2.0	15
3	A Comprehensive Assessment of <sup>68</sup> Ga-PSMA-11 PET in Biochemically Recurrent Prostate Cancer: Results from a Prospective Multicenter Study on 2,005 Patients. <i>Journal of Nuclear Medicine</i> , 2022, 63, 567-572.	2.8	20
4	Cancer Misinformation and Harmful Information on Facebook and Other Social Media: A Brief Report. <i>Journal of the National Cancer Institute</i> , 2022, 114, 1036-1039.	3.0	74
5	A transcriptomic model for homologous recombination deficiency in prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 659-665.	2.0	9
6	Prospective Multicenter Comparison of Open and Robotic Radical Prostatectomy: The PROST-QA/RP2 Consortium. <i>Journal of Urology</i> , 2022, 207, 127-136.	0.2	7
7	Pan-cancer analysis of prognostic metastatic phenotypes. <i>International Journal of Cancer</i> , 2022, 150, 132-141.	2.3	19
8	Racial disparities in prostate cancer among black men: epidemiology and outcomes. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 397-402.	2.0	37
9	Reporting of Racial Health Disparities Research: Are We Making Progress?. <i>Journal of Clinical Oncology</i> , 2022, 40, 8-11.	0.8	11
10	Association Between Physician- and Patient-Reported Symptoms in Patients Treated With Definitive Radiation Therapy for Locally Advanced Lung Cancer in a Statewide Consortium. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 942-950.	0.4	7
11	TrueNTH Sexual Recovery Intervention for couples coping with prostate cancer: Randomized controlled trial results. <i>Cancer</i> , 2022, 128, 1513-1522.	2.0	12
12	Clinicogenomic characterization of prostate cancer liver metastases. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 366-369.	2.0	7
13	Should brachytherapy be added to external beam radiotherapy for prostate cancer?. <i>Lancet Oncology</i> , The, 2022, 23, 23-25.	5.1	6
14	TERT Promoter Mutations in Keratinizing and Nonkeratinizing Squamous Metaplasia of the Urinary Tract. <i>European Urology Open Science</i> , 2022, 35, 74-78.	0.2	4
15	Radiotherapy for Advanced Prostate Cancer. , 2022, , 197-213.		1
16	Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis. <i>Lancet Oncology</i> , The, 2022, 23, 304-316.	5.1	68
17	Racial Differences in Treatments and Toxicity in Patients With Non-Small-Cell Lung Cancer Treated With Thoracic Radiation Therapy. <i>JCO Oncology Practice</i> , 2022, , OP2100224.	1.4	0
18	Identification and Validation of the Prognostic Impact of Metastatic Prostate Cancer Phenotypes. <i>Clinical Genitourinary Cancer</i> , 2022, , .	0.9	1

#	ARTICLE	IF	CITATIONS
19	Quantitative Nodal Burden and Mortality Across Solid Cancers. Journal of the National Cancer Institute, 2022, 114, 1003-1011.	3.0	4
20	Development and Validation of a Life Expectancy Calculator for U.S. Prostate Cancer Patients. BJU International, 2022, , .	1.3	2
21	An Expert Review on the Combination of Relugolix With Definitive Radiation Therapy for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2022, 113, 278-289.	0.4	4
22	Intensification of Systemic Therapy in Addition to Definitive Local Treatment in Nonmetastatic Unfavourable Prostate Cancer: A Systematic Review and Meta-analysis. European Urology, 2022, 82, 82-96.	0.9	15
23	High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patientâ€“data Network Meta-analysis from the MARCAP Consortium. European Urology, 2022, 82, 106-114.	0.9	19
24	Leveraging artificial intelligence to predict ERG gene fusion status in prostate cancer. BMC Cancer, 2022, 22, 494.	1.1	8
25	Bicalutamide Monotherapy With Radiation Therapy for Localized Prostate Cancer: A Non-Evidence-Based Alternative. International Journal of Radiation Oncology Biology Physics, 2022, 113, 316-319.	0.4	0
26	MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets. Nature Communications, 2022, 13, 2559.	5.8	56
27	Harm-to-Benefit of Three Decades of Prostate Cancer Screening in Black Men. , 2022, 1, .		23
28	Genomic biomarkers to guide precision radiotherapy in prostate cancer. Prostate, 2022, 82, .	1.2	3
29	Biochemical Failure Is Not a Surrogate End Point for Overall Survival in Recurrent Prostate Cancer: Analysis of NRG Oncology/RTOC 9601. Journal of Clinical Oncology, 2022, 40, 3172-3179.	0.8	14
30	A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER). European Urology, 2021, 80, 280-292.	0.9	140
31	Low Utilization of Androgen Deprivation Therapy Among Men Receiving Stereotactic Body Radiotherapy for Localized Prostate Cancer in the United States. European Urology Oncology, 2021, 4, 337-338.	2.6	0
32	NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Postoperative Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2021, 109, 174-185.	0.4	77
33	Doseâ€“response with stereotactic body radiotherapy for prostate cancer: A multi-institutional analysis of prostate-specific antigen kinetics and biochemical control. Radiotherapy and Oncology, 2021, 154, 207-213.	0.3	24
34	Prostate-specific Membrane Antigen Positron Emission Tomographyâ€“guided Radiotherapy. European Urology Focus, 2021, 7, 250-253.	1.6	6
35	A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer. European Urology, 2021, 79, 374-383.	0.9	93
36	Prostate Radiotherapy With Adjuvant Androgen Deprivation Therapy (ADT) Improves Metastasis-Free Survival Compared to Neoadjuvant ADT: An Individual Patient Meta-Analysis. Journal of Clinical Oncology, 2021, 39, 136-144.	0.8	52

#	ARTICLE	IF	CITATIONS
37	Underutilization of Androgen Deprivation Therapy with External Beam Radiotherapy in Men with High-grade Prostate Cancer. <i>European Urology Oncology</i> , 2021, 4, 327-330.	2.6	3
38	The Management of Prostate Cancer. <i>Practical Guides in Radiation Oncology</i> , 2021, , 3-23.	0.0	0
39	Nonmetastatic castration-resistant prostate cancer: Novel agents to treat a lethal disease. <i>World Journal of Clinical Oncology</i> , 2021, 12, 6-12.	0.9	3
40	Plasma cells are enriched in localized prostate cancer in Black men and are associated with improved outcomes. <i>Nature Communications</i> , 2021, 12, 935.	5.8	56
41	Treating the patient and not just the cancer: therapeutic burden in prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 647-661.	2.0	25
42	De novo neuroendocrine transdifferentiation in primary prostate cancer—a phenotype associated with advanced clinico-pathologic features and aggressive outcome. <i>Medical Oncology</i> , 2021, 38, 26.	1.2	18
43	Efficacy and Incontinence Rates After Urethroplasty for Radiation-induced Urethral Stenosis: A Systematic Review and Meta-analysis. <i>Urology</i> , 2021, 152, 109-116.	0.5	3
44	Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis. <i>Lancet Oncology</i> , The, 2021, 22, 402-410.	5.1	79
45	Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer. <i>JAMA Oncology</i> , 2021, 7, 544.	3.4	82
46	TRIM63 is a sensitive and specific biomarker for MiT family aberration-associated renal cell carcinoma. <i>Modern Pathology</i> , 2021, 34, 1596-1607.	2.9	17
47	Survival, fusion, and hardware failure after surgery for spinal metastatic disease. <i>Journal of Neurosurgery: Spine</i> , 2021, 34, 665-672.	0.9	6
48	Importance of radiotherapy to the primary in metastatic hormone sensitive prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 929-930.	2.0	0
49	Factors Influencing Noncompletion of Radiation Therapy Among Men With Localized Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 1279-1285.	0.4	18
50	Evaluation of predictive model performance of an existing model in the presence of missing data. <i>Statistics in Medicine</i> , 2021, 40, 3477-3498.	0.8	2
51	Management of Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy: A Systematic Review of the Literature. <i>European Urology Oncology</i> , 2021, 4, 150-169.	2.6	23
52	Olaparib vs Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer. <i>JAMA Network Open</i> , 2021, 4, e2110950.	2.8	4
53	Impact of Treating Physician on Radiation Therapy Related Severe Toxicities in Men with Prostate Cancer. <i>Practical Radiation Oncology</i> , 2021, 11, e292-e300.	1.1	2
54	Contemporary Practice Patterns for Palliative Radiation Therapy of Bone Metastases: Impact of a Quality Improvement Project on Extended Fractionation. <i>Practical Radiation Oncology</i> , 2021, 11, e498-e505.	1.1	4

#	ARTICLE	IF	CITATIONS
55	Comparative analysis of 1152 African-American and European-American men with prostate cancer identifies distinct genomic and immunological differences. <i>Communications Biology</i> , 2021, 4, 670.	2.0	50
56	Prostate-specific Membrane Antigen and Fluciclovine Transporter Genes are Associated with Variable Clinical Features and Molecular Subtypes of Primary Prostate Cancer. <i>European Urology</i> , 2021, 79, 717-721.	0.9	13
57	BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program. <i>Clinical Cancer Research</i> , 2021, 27, 4923-4936.	3.2	33
58	Predictors of Pneumonitis After Conventionally Fractionated Radiotherapy for Locally Advanced Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 1176-1185.	0.4	21
59	Reply to S. Sundar et al and S. HÃ¶rcht et al. <i>Journal of Clinical Oncology</i> , 2021, 39, 2316-2317.	0.8	0
60	Comparison of Multimodal Therapies and Outcomes Among Patients With High-Risk Prostate Cancer With Adverse Clinicopathologic Features. <i>JAMA Network Open</i> , 2021, 4, e2115312.	2.8	12
61	Photons, Protons, SBRT, Brachytherapy—What Is Leading the Charge for the Management of Prostate Cancer? A Perspective From the GU Editorial Team. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 1114-1121.	0.4	4
62	Drivers of racial disparities in prostate cancer trial enrollment. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 946-947.	2.0	4
63	Dose Escalation for Oligometastatic Disease: Is More Better?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 680-681.	0.4	2
64	Radiation therapy dose and androgen deprivation therapy in localized prostate cancer: a meta-regression of 5-year outcomes in phase III randomized controlled trials. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, , .	2.0	8
65	Salvage therapy for prostate cancer after radical prostatectomy. <i>Nature Reviews Urology</i> , 2021, 18, 643-668.	1.9	26
66	Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer. <i>European Urology</i> , 2021, 80, 142-146.	0.9	12
67	End Point Definitions and Surrogacy in Prostate Cancer: Will Metastasis-Free Survival Become Event-Free Survival With Advances in Molecular Imaging?. <i>Journal of Clinical Oncology</i> , 2021, 39, 2844-2845.	0.8	4
68	Exercise: A Treatment That Should Be Prescribed With Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, , .	0.4	0
69	Re: Safety and Efficacy of Virtual Prostatectomy with Single-dose Radiotherapy in Patients with Intermediate-risk Prostate Cancer: Results from the PROSINT Phase 2 Randomized Clinical Trial. <i>European Urology</i> , 2021, 80, 674-675.	0.9	0
70	Prostate SBRT Dose Escalation (9 Gy—5, 13.3 Gy—3, 24 Gy—1): Are We Making Progress?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 110-112.	0.4	0
71	An international Delphi consensus for pelvic stereotactic ablative radiotherapy re-irradiation. <i>Radiotherapy and Oncology</i> , 2021, 164, 104-114.	0.3	10
72	Impact of Decipher on use of postoperative radiotherapy: Individual patient analysis of two prospective registries. <i>BJUI Compass</i> , 2021, 2, 267-274.	0.7	7

#	ARTICLE	IF	CITATIONS
73	Development and Validation of an Improved Pathological Nodal Staging System in Men With Prostate Cancer. <i>Journal of Urology</i> , 2021, , 101097JU00000000000002256.	0.2	4
74	Elective Nodal Radiotherapy for Prostate Cancer: For None, Some, or all?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 965-967.	0.4	3
75	Race and Genetic Alterations in Prostate Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 1650-1653.	1.5	12
76	MRI-Targeted Biopsy in Prostate Cancer Screening. <i>New England Journal of Medicine</i> , 2021, 385, 2109-2111.	13.9	2
77	Case Report: Role of an Iodinated Rectal Hydrogel Spacer, SpaceOAR Vue, in the Context of Low-Dose-Rate Prostate Brachytherapy, for Enhanced Post-Operative Contouring to Aid in Accurate Implant Evaluation and Dosimetry. <i>Frontiers in Oncology</i> , 2021, 11, 810955.	1.3	2
78	Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer. <i>JAMA Network Open</i> , 2021, 4, e2138550.	2.8	18
79	Comparison of Response to Definitive Radiotherapy for Localized Prostate Cancer in Black and White Men. <i>JAMA Network Open</i> , 2021, 4, e2139769.	2.8	16
80	Prostate-only Versus Whole-pelvis Radiation with or Without a Brachytherapy Boost for Gleason Grade Group 5 Prostate Cancer: A Retrospective Analysis. <i>European Urology</i> , 2020, 77, 3-10.	0.9	18
81	Prospective study to define the clinical utility and benefit of Decipher testing in men following prostatectomy. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 295-302.	2.0	30
82	Local Failure and Survival After Definitive Radiotherapy for Aggressive Prostate Cancer: An Individual Patient-level Meta-analysis of Six Randomized Trials. <i>European Urology</i> , 2020, 77, 201-208.	0.9	37
83	PAX8 expression and TERT promoter mutations in the nested variant of urothelial carcinoma: a clinicopathologic study with immunohistochemical and molecular correlates. <i>Modern Pathology</i> , 2020, 33, 1165-1171.	2.9	18
84	Stereotactic Ablative Radiotherapy for the Management of Spinal Metastases. <i>JAMA Oncology</i> , 2020, 6, 567.	3.4	64
85	Genomic and clinical characterization of stromal infiltration markers in prostate cancer. <i>Cancer</i> , 2020, 126, 1407-1412.	2.0	8
86	Androgen deprivation therapy plus salvage radiotherapy after prostatectomy. <i>Lancet Oncology</i> , The, 2020, 21, e12.	5.1	0
87	Validation of a genomic classifier for prediction of metastasis and prostate cancer-specific mortality in African-American men following radical prostatectomy in an equal access healthcare setting. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 419-428.	2.0	22
88	TERT- beyond the territory: Usage of PCR-based TERT promoter assay in defining urothelial carcinoma in a case of long-standing prostatic adenocarcinoma. <i>Pathology Research and Practice</i> , 2020, 216, 152663.	1.0	1
89	Why the UK Should Consider Gene Expression Testing in Prostate Cancer. <i>Clinical Oncology</i> , 2020, 32, 149-155.	0.6	1
90	Clinical Utility of a Genomic Classifier in Men Undergoing Radical Prostatectomy: The PRO-IMPACT Trial. <i>Practical Radiation Oncology</i> , 2020, 10, e82-e90.	1.1	19

#	ARTICLE	IF	CITATIONS
91	Correlation between cribriform/intraductal prostatic adenocarcinoma and percent Gleason pattern 4 to a 22â€ gene genomic classifier. <i>Prostate</i> , 2020, 80, 146-152.	1.2	21
92	Clinicopathological characterisation of renal cell carcinoma in young adults: a contemporary update and review of literature. <i>Histopathology</i> , 2020, 76, 875-887.	1.6	7
93	Absolute versus Relative Benefit of Androgen Deprivation Therapy for Prostate Cancer: Moving Beyond the Hazard Ratio to Personalize Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 899-902.	0.4	7
94	The Impact of the COVID-19 Pandemic on Genitourinary Cancer Care: Re-envisioning the Future. <i>European Urology</i> , 2020, 78, 731-742.	0.9	39
95	Development and Validation of a Genomic Tool to Predict Seminal Vesicle Invasion in Adenocarcinoma of the Prostate. <i>JCO Precision Oncology</i> , 2020, 4, 1228-1238.	1.5	2
96	Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results From the International Staging Collaboration for Cancer of the Prostate. <i>JAMA Oncology</i> , 2020, 6, 1912.	3.4	49
97	ARe we there yet? Understanding androgen receptor signaling in breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 47.	2.3	57
98	Editorial: Optimizing Local Therapy for High-Risk Prostate Cancer: Evidence and Emerging Options. <i>Frontiers in Oncology</i> , 2020, 10, 1616.	1.3	1
99	The DNA methylation landscape of advanced prostate cancer. <i>Nature Genetics</i> , 2020, 52, 778-789.	9.4	198
100	Prostate-specific antigen kinetics and biochemical control following stereotactic body radiation therapy, high dose rate brachytherapy, and low dose rate brachytherapy: A multi-institutional analysis of 3502 patients. <i>Radiotherapy and Oncology</i> , 2020, 151, 26-32.	0.3	19
101	Expression of the Androgen Receptor Governs Radiation Resistance in a Subset of Glioblastomas Vulnerable to Antiandrogen Therapy. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2163-2174.	1.9	17
102	Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19. <i>Advances in Radiation Oncology</i> , 2020, 5, 26-32.	0.6	19
103	Cancer Treatment Decision-Making During the COVID-19 Pandemic: Data Over Opinion. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 338-339.	0.4	1
104	Racial Differences in Genomic Profiling of Prostate Cancer. <i>New England Journal of Medicine</i> , 2020, 383, 1083-1085.	13.9	87
105	Effect of Androgen Deprivation on Long-term Outcomes of Intermediate-Risk Prostate Cancer Stratified as Favorable or Unfavorable. <i>JAMA Network Open</i> , 2020, 3, e2015083.	2.8	30
106	Integrated Survival Estimates for Cancer Treatment Delay Among Adults With Cancer During the COVID-19 Pandemic. <i>JAMA Oncology</i> , 2020, 6, 1881.	3.4	66
107	Changes in prostateâ€ specific antigen at the time of prostate cancer diagnosis after Medicaid expansion in young men. <i>Cancer</i> , 2020, 126, 3229-3236.	2.0	9
108	Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 12315-12323.	3.3	87

#	ARTICLE	IF	CITATIONS
109	Association or Causality: Does Whole Brain Proton Radiotherapy Not Impact IQ?. <i>Journal of Clinical Oncology</i> , 2020, 38, 2211-2212.	0.8	2
110	Addition of Androgen-Deprivation Therapy or Brachytherapy Boost to External Beam Radiotherapy for Localized Prostate Cancer: A Network Meta-Analysis of Randomized Trials. <i>Journal of Clinical Oncology</i> , 2020, 38, 3024-3031.	0.8	26
111	Challenging the Norm: What Level of Evidence Is Necessary to Adopt Postprostatectomy Hypofractionated Radiation Therapy?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 297-298.	0.4	4
112	Transcriptomic Heterogeneity of Gleason Grade Group 5 Prostate Cancer. <i>European Urology</i> , 2020, 78, 327-332.	0.9	18
113	Impact of Sequencing of Androgen Suppression and Radiation Therapy on Testosterone Recovery in Localized Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 1179-1188.	0.4	10
114	Cost-Effectiveness of Metastasis-Directed Therapy in Oligorecurrent Hormone-Sensitive Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 917-926.	0.4	11
115	Clinical Applications of Molecular Biomarkers in Prostate Cancer. <i>Cancers</i> , 2020, 12, 1550.	1.7	21
116	Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation. <i>Journal of Clinical Oncology</i> , 2020, 38, 3032-3041.	0.8	37
117	BRAINSTORM: A Multi-Institutional Phase 1/2 Study of RRx-001 in Combination With Whole Brain Radiation Therapy for Patients With Brain Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 478-486.	0.4	6
118	Evolving Role of Stereotactic Body Radiation Therapy in the Management of Spine Metastases. <i>Neurosurgery Clinics of North America</i> , 2020, 31, 167-189.	0.8	12
119	Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer. <i>JAMA Oncology</i> , 2020, 6, 735.	3.4	58
120	Tumor Immune Microenvironment Clusters in Localized Prostate Adenocarcinoma: Prognostic Impact of Macrophage Enriched/Plasma Cell Non-Enriched Subtypes. <i>Journal of Clinical Medicine</i> , 2020, 9, 1973.	1.0	10
121	Polypoidal giant cancer cells in metastatic castration-resistant prostate cancer: observations from the Michigan Legacy Tissue Program. <i>Medical Oncology</i> , 2020, 37, 16.	1.2	13
122	Seviteronel, a Novel CYP17 Lyase Inhibitor and Androgen Receptor Antagonist, Radiosensitizes AR-Positive Triple Negative Breast Cancer Cells. <i>Frontiers in Endocrinology</i> , 2020, 11, 35.	1.5	24
123	Detecting TRA-160 in Cancer via a Novel Zr-89 Labeled ImmunoPET Imaging Agent. <i>Molecular Pharmaceutics</i> , 2020, 17, 1139-1147.	2.3	6
124	<i>CDKN1B</i> Deletions are Associated with Metastasis in African American Men with Clinically Localized, Surgically Treated Prostate Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 2595-2602.	3.2	16
125	Performance of clinicopathologic models in men with high risk localized prostate cancer: impact of a 22-gene genomic classifier. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 646-653.	2.0	17
126	Clinical-genomic Characterization Unveils More Aggressive Disease Features in Elderly Prostate Cancer Patients with Low-grade Disease. <i>European Urology Focus</i> , 2020, 7, 797-806.	1.6	1

#	ARTICLE	IF	CITATIONS
127	Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19. <i>Advances in Radiation Oncology</i> , 2020, 5, 659-665.	0.6	149
128	Radiation-Induced Insufficiency Fractures After Pelvic Irradiation for Gynecologic Malignancies: A Systematic Review. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 620-634.	0.4	30
129	Editorial Comment. <i>Journal of Urology</i> , 2020, 204, 89-90.	0.2	0
130	The Finnish Randomized Trial of Adjuvant Radiotherapy Versus Observation After Prostatectomy: Almost a Trial of Adjuvant Versus Late Salvage Radiotherapy. <i>European Urology</i> , 2019, 76, 596-598.	0.9	2
131	Analysis of Outcomes Between Traditional Open versus Mini-Open Approach in Surgical Treatment of Spinal Metastasis. <i>World Neurosurgery</i> , 2019, 130, e467-e474.	0.7	16
132	Long-Term Benefits of Dose-Escalation in Localized Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 798-800.	0.4	6
133	Adjuvant Radiation Improves Recurrence-Free Survival and Overall Survival in Adrenocortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 3743-3750.	1.8	35
134	Clinical and morphologic review of 60 hereditary renal tumors from 30 hereditary renal cell carcinoma syndrome patients: lessons from a contemporary single institution series. <i>Medical Oncology</i> , 2019, 36, 74.	1.2	15
135	Conservative management of low-risk prostate cancer among young versus older men in the United States: Trends and outcomes from a novel national database. <i>Cancer</i> , 2019, 125, 3338-3346.	2.0	15
136	DNA-Dependent Protein Kinase Drives Prostate Cancer Progression through Transcriptional Regulation of the Wnt Signaling Pathway. <i>Clinical Cancer Research</i> , 2019, 25, 5608-5622.	3.2	17
137	Circulating Tumor Cell-Based Molecular Classifier for Predicting Resistance to Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer. <i>Neoplasia</i> , 2019, 21, 802-809.	2.3	32
138	SBRT for Localized Prostate Cancer: Is it Ready for Take-Off?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 618-620.	0.4	7
139	Recommendations for Single-Fraction Radiation Therapy and Stereotactic Body Radiation Therapy in Palliative Treatment of Bone Metastases: A Statewide Practice Patterns Survey. <i>Practical Radiation Oncology</i> , 2019, 9, e541-e548.	1.1	10
140	Genomic Risk Predicts Molecular Imaging-detected Metastatic Nodal Disease in Prostate Cancer. <i>European Urology</i> , 2019, 2, 685-690.	2.6	21
141	Genomic Validation of 3-Tiered Clinical Subclassification of High-Risk Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 621-627.	0.4	10
142	Reply to J.R. Rider et al. <i>Journal of Clinical Oncology</i> , 2019, 37, 2696-2697.	0.8	0
143	A Video Decision Aid Improves Informed Decision Making in Patients With Advanced Cancer Considering Palliative Radiation Therapy. <i>Journal of Pain and Symptom Management</i> , 2019, 58, 1048-1055.e2.	0.6	13
144	High-fat diet fuels prostate cancer progression by rewiring the metabolome and amplifying the MYC program. <i>Nature Communications</i> , 2019, 10, 4358.	5.8	109

#	ARTICLE	IF	CITATIONS
145	Population-Based Observational Studies in Oncology: Proceed With Caution. <i>Seminars in Radiation Oncology</i> , 2019, 29, 302-305.	1.0	5
146	Multi-Institutional Analysis of Prostate-Specific Antigen Kinetics After Stereotactic Body Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 628-636.	0.4	20
147	Local Control and Toxicity of Multilevel Spine Stereotactic Body Radiotherapy. <i>Neurosurgery</i> , 2019, 86, E164-E172.	0.6	5
148	Re: Sebastian Berg, Alexander P. Cole, Marieke J. Krimphove, et al. Comparative Effectiveness of Radical Prostatectomy Versus External Beam Radiation Therapy Plus Brachytherapy in Patients with High-risk Localized Prostate Cancer. <i>Eur Urol</i> 2019;75:552-5. <i>European Urology</i> , 2019, 75, e133-e134.	0.9	0
149	Prostate Cancer Genomic-risk Differences Between African-American and White Men Across Gleason Scores. <i>European Urology</i> , 2019, 75, 1038-1040.	0.9	38
150	Individual and Population Comparisons of Surgery and Radiotherapy Outcomes in Prostate Cancer Using Bayesian Multistate Models. <i>JAMA Network Open</i> , 2019, 2, e187765.	2.8	17
151	Xenograft-based, platform-independent gene signatures to predict response to alkylating chemotherapy, radiation, and combination therapy for glioblastoma. <i>Neuro-Oncology</i> , 2019, 21, 1141-1149.	0.6	17
152	Association of Black Race With Prostate Cancer-Specific and Other-Cause Mortality. <i>JAMA Oncology</i> , 2019, 5, 975.	3.4	288
153	Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 778-789.	0.4	247
154	A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA). <i>BMC Cancer</i> , 2019, 19, 572.	1.1	3
155	Key considerations when reviewing subsequent primary cancers following radiotherapy. <i>Lancet Oncology</i> , The, 2019, 20, e291.	5.1	1
156	Active Surveillance for Low-Risk Prostate Cancer in Black Patients. <i>New England Journal of Medicine</i> , 2019, 380, 2070-2072.	13.9	42
157	The State of the Science on Prostate Cancer Biomarkers: The San Francisco Consensus Statement. <i>European Urology</i> , 2019, 76, 268-272.	0.9	28
158	The current state of randomized clinical trial evidence for prostate brachytherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 599-610.	0.8	8
159	Tumor. <i>Operative Neurosurgery</i> , 2019, 17, S119-S152.	0.4	3
160	What Are We Even Looking At?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 264-265.	0.4	1
161	Utilization of Salvage Radiation Therapy for Biochemical Recurrence After Radical Prostatectomy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 1030-1034.	0.4	20
162	STAMPEDE: Is Radiation Therapy to the Primary a New Standard of Care in Men with Metastatic Prostate Cancer?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 33-35.	0.4	8

#	ARTICLE	IF	CITATIONS
163	Dose-intensified chemoradiation is associated with altered patterns of failure and favorable survival in patients with newly diagnosed glioblastoma. <i>Journal of Neuro-Oncology</i> , 2019, 143, 313-319.	1.4	11
164	Computed Tomography Myelosimulation Versus Magnetic Resonance Imaging Registration to Delineate the Spinal Cord During Spine Stereotactic Radiosurgery. <i>World Neurosurgery</i> , 2019, 122, e655-e666.	0.7	8
165	Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer. <i>JAMA Network Open</i> , 2019, 2, e188006.	2.8	221
166	Use of Active Surveillance or Watchful Waiting for Low-Risk Prostate Cancer and Management Trends Across Risk Groups in the United States, 2010-2015. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 704.	3.8	168
167	Combination therapies in prostate cancer: proceed with caution. <i>Lancet Oncology</i> , The, 2019, 20, 321-323.	5.1	9
168	Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a <i>de novo</i> low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 6721-6730.	3.2	74
169	Thyroid Cancer Brain Metastasis. <i>Clinical Nuclear Medicine</i> , 2019, 44, 544-549.	0.7	13
170	Biology vs Access to Care—Relative Contribution to Racial Disparities in Prostate Cancer—In Reply. <i>JAMA Oncology</i> , 2019, 5, 1810.	3.4	0
171	Contemporary Renal Tumor Categorization With Biomarker and Translational Updates: A Practical Review. <i>Archives of Pathology and Laboratory Medicine</i> , 2019, 143, 1477-1491.	1.2	9
172	Seeking Consistency in Guidelines: Level of Evidence, Trial Endpoints, and Personalized Recommendations. <i>Practical Radiation Oncology</i> , 2019, 9, 496-500.	1.1	1
173	Tissue-based genomics. <i>Current Opinion in Urology</i> , 2019, 29, 598-604.	0.9	3
174	Application of a Prognostic Stratification System for High-risk Prostate Cancer to Patients Treated With Radiotherapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 382-390.	0.6	3
175	Thyroid Cancer Bone Metastasis. <i>Clinical Nuclear Medicine</i> , 2019, 44, e465-e471.	0.7	22
176	Circulating Tumor Cells as a Predictor of Treatment Response in Clinically Localized Prostate Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-9.	1.5	18
177	Association of Gleason Grade With Androgen Deprivation Therapy Duration and Survival Outcomes. <i>JAMA Oncology</i> , 2019, 5, 91.	3.4	27
178	Adverse events in radiation oncology: A case series from wake up safe, the pediatric anesthesia quality improvement initiative. <i>Paediatric Anaesthesia</i> , 2019, 29, 265-270.	0.6	16
179	Precision Medicine for Localized Prostate Cancer: Time to Move Beyond NCCN Risk Stratification?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 92-94.	0.4	4
180	Clinical and Genomic Implications of Luminal and Basal Subtypes Across Carcinomas. <i>Clinical Cancer Research</i> , 2019, 25, 2450-2457.	3.2	52

#	ARTICLE	IF	CITATIONS
181	National practice patterns for lymph node irradiation in 197,000 men receiving external beam radiotherapy for localized prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 353.e1-353.e8.	0.8	2
182	Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9-10 Prostate Cancer. <i>European Urology</i> , 2019, 75, 35-41.	0.9	18
183	The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target. <i>Journal of the National Cancer Institute</i> , 2019, 111, 301-310.	3.0	142
184	Clinical utility and concordance of upper urinary tract cytology and biopsy in predicting clinicopathological features of upper urinary tract urothelial carcinoma. <i>Human Pathology</i> , 2019, 86, 76-84.	1.1	16
185	Re: Marco Moschini, Emanuele Zaffuto, Pierre I. Karakiewicz, et al. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis. <i>Eur Urol</i> 2019;75:319-28. <i>European Urology</i> , 2019, 75, e96-e97.	0.9	1
186	Risk of Upgrading and Upstaging Among 10 000 Patients with Gleason 3 + 4 Favorable Intermediate-risk Prostate Cancer. <i>European Urology Focus</i> , 2019, 5, 69-76.	1.6	40
187	Prostate Cancer Transcriptomic Subtypes. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1210, 111-120.	0.8	5
188	Metastatic castration resistant prostate cancer with squamous cell, small cell, and sarcomatoid elements—a clinicopathologic and genomic sequencing-based discussion. <i>Medical Oncology</i> , 2019, 36, 27.	1.2	8
189	Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 479-505.	2.3	943
190	Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 896.	3.8	252
191	Changes in prostate orientation due to removal of a Foley catheter. <i>Medical Physics</i> , 2018, 45, 1369-1378.	1.6	13
192	Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer. <i>European Urology</i> , 2018, 74, 146-154.	0.9	72
193	Mentorship Experiences of Early-Career Academic Radiation Oncologists in North America. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 732-740.	0.4	29
194	Improving Quality and Consistency in NRG Oncology Radiation Therapy Oncology Group 0631 for Spine Radiosurgery via Knowledge-Based Planning. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 1067-1074.	0.4	35
195	Standard dose and dose-escalated radiation therapy are associated with favorable survival in select elderly patients with newly diagnosed glioblastoma. <i>Journal of Neuro-Oncology</i> , 2018, 138, 155-162.	1.4	4
196	Detailed pathologic analysis on the co-occurrence of non-seminomatous germ cell tumor subtypes in matched orchiectomy and retroperitoneal lymph node dissections. <i>Medical Oncology</i> , 2018, 35, 21.	1.2	3
197	Comparison Between Adjuvant and Early-Salvage Postprostatectomy Radiotherapy for Prostate Cancer With Adverse Pathological Features. <i>JAMA Oncology</i> , 2018, 4, e175230.	3.4	65
198	Intermediate Endpoints After Postprostatectomy Radiotherapy: 5-Year Distant Metastasis to Predict Overall Survival. <i>European Urology</i> , 2018, 74, 413-419.	0.9	29

#	ARTICLE	IF	CITATIONS
199	Contemporary Statewide Practice Pattern Assessment of the Palliative Treatment of Bone Metastasis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 462-467.	0.4	16
200	Patient-Reported Sexual Aid Utilization and Efficacy After Radiation Therapy for Localized Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 376-386.	0.4	7
201	Self-reported Conflicts of Interest and Trial Sponsorship of Clinical Trials in Prostate Cancer Involving Radiotherapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 6-12.	0.6	4
202	Erectile function after stereotactic body radiotherapy for localized prostate cancer. <i>BJU International</i> , 2018, 121, 61-68.	1.3	24
203	A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer. <i>European Urology</i> , 2018, 73, 156-165.	0.9	55
204	A multi-institutional phase 2 trial of prostate stereotactic body radiation therapy (SBRT) using continuous real-time evaluation of prostate motion with patient-reported quality of life. <i>Practical Radiation Oncology</i> , 2018, 8, 40-47.	1.1	27
205	Estimating the Optimal Personalized Treatment Strategy Based on Selected Variables to Prolong Survival via Random Survival Forest with Weighted Bootstrap. <i>Journal of Biopharmaceutical Statistics</i> , 2018, 28, 362-381.	0.4	9
206	Radiosurgery for Treatment of Renal Cell Metastases to Spine: A Systematic Review of the Literature. <i>World Neurosurgery</i> , 2018, 109, e502-e509.	0.7	25
207	Performance of a Prostate Cancer Genomic Classifier in Predicting Metastasis in Men with Prostate-specific Antigen Persistence Postprostatectomy. <i>European Urology</i> , 2018, 74, 107-114.	0.9	54
208	Funding source, conflict of interest and positive conclusions in neuro-oncology clinical trials. <i>Journal of Neuro-Oncology</i> , 2018, 136, 585-593.	1.4	5
209	Travel distance and stereotactic body radiotherapy for localized prostate cancer. <i>Cancer</i> , 2018, 124, 1141-1149.	2.0	21
210	Natural history of "second" biochemical failure after salvage radiation therapy for prostate cancer: a multi-institution study. <i>BJU International</i> , 2018, 121, 365-372.	1.3	12
211	Reply to Pirus Ghadjar and Thomas Wiegel's Letter to the Editor re: Daniel E. Spratt, Robert T. Dess, Zachary S. Zumsteg, et al. A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer. <i>Eur Urol</i> 2018;73:156-65. <i>European Urology</i> , 2018, 73, e64-e65.	0.9	2
212	Multi-institutional Evaluation of Elective Nodal Irradiation and/or Androgen Deprivation Therapy with Postprostatectomy Salvage Radiotherapy for Prostate Cancer. <i>European Urology</i> , 2018, 74, 99-106.	0.9	28
213	Clinical Utility of Gene Expression Classifiers in Men With Newly Diagnosed Prostate Cancer. <i>JCO Precision Oncology</i> , 2018, 2, 1-15.	1.5	13
214	Management of Biochemically Recurrent Prostate Cancer: Ensuring the Right Treatment of the Right Patient at the Right Time. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 355-362.	1.8	28
215	Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 581-590.	0.8	162
216	Optimal Radical Therapy for Localized Prostate Cancer: Recreation of the Self-Fulfilling Prophecy With Combination Brachytherapy?. <i>Journal of Clinical Oncology</i> , 2018, 36, 2914-2917.	0.8	16

#	ARTICLE	IF	CITATIONS
217	Genomic biomarkers in prostate cancer. <i>Translational Andrology and Urology</i> , 2018, 7, 459-471.	0.6	46
218	Re: Amar U. Kishan, Rahul D. Tendulkar, Phuoc T. Tran, et al. Optimizing the Timing of Salvage Postprostatectomy Radiotherapy and the Use of Concurrent Hormonal Therapy for Prostate Adenocarcinoma. <i>Eur Urol Oncol</i> . In press. <i>European Urology Oncology</i> , 2018, 1, 323-324.	2.6	1
219	Impact of Biochemical Failure After Salvage Radiation Therapy on Prostate Cancer-specific Mortality: Competition Between Age and Time to Biochemical Failure. <i>European Urology Oncology</i> , 2018, 1, 276-282.	2.6	6
220	In Reply to Wilkins et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 1597-1598.	0.4	0
221	Genomics, bio specimens, and other biological data: Current status and future directions. <i>Medical Physics</i> , 2018, 45, e829-e833.	1.6	3
222	DIPG-23. BRAINSTEM RADIATION EXPOSURE CONFERS SUBSTANTIAL RISK OF DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) IN MEDULLOBLASTOMA SURVIVORS: A REPORT FROM THE INTERNATIONAL DIPG REGISTRY. <i>Neuro-Oncology</i> , 2018, 20, i53-i53.	0.6	0
223	Evidence-based Risk Stratification to Guide Hormone Therapy Use With Salvage Radiation Therapy for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 556-560.	0.4	6
224	Predominance of Spinal Metastases Involving the Posterior Vertebral Body. <i>World Neurosurgery</i> , 2018, 119, e991-e996.	0.7	10
225	Are we inadvertently widening the disparity gap in pursuit of precision oncology?. <i>British Journal of Cancer</i> , 2018, 119, 783-784.	2.9	9
226	Development and Validation of a Prostate Cancer Genomic Signature that Predicts Early ADT Treatment Response Following Radical Prostatectomy. <i>Clinical Cancer Research</i> , 2018, 24, 3908-3916.	3.2	24
227	Ki-67 Remains Solely a Prognostic Biomarker in Localized Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 513-515.	0.4	8
228	Surgical Approach to Bone Metastases. <i>Current Osteoporosis Reports</i> , 2018, 16, 512-518.	1.5	10
229	Clinical Outcomes for Patients With Gleason Score 10 Prostate Adenocarcinoma: Results From a Multi-institutional Consortium Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 883-888.	0.4	10
230	Frequent PD-L1 Protein Expression and Molecular Correlates in Urinary Bladder Squamous Cell Carcinoma. <i>European Urology</i> , 2018, 74, 529-531.	0.9	17
231	The relationship of study and authorship characteristics on trial sponsorship and self-reported conflicts of interest among neuro-oncology clinical trials. <i>Journal of Neuro-Oncology</i> , 2018, 139, 195-203.	1.4	4
232	Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. <i>Cell</i> , 2018, 174, 758-769.e9.	13.5	459
233	Medulloblastoma therapy generates risk of a poorly-prognostic H3 wild-type subgroup of diffuse intrinsic pontine glioma: a report from the International DIPG Registry. <i>Acta Neuropathologica Communications</i> , 2018, 6, 67.	2.4	12
234	Transcriptomic Heterogeneity of Favorable-risk Prostate Cancer: Time To Move Past Cancer of the Prostate Risk Assessment (CAPRA) to Clinical-genomic Risk. <i>European Urology</i> , 2018, 74, 453-454.	0.9	1

#	ARTICLE	IF	CITATIONS
235	Adjuvant Radiation Therapy for High-Risk Post-prostatectomy Patients. , 2018, , 81-99.		0
236	Programmed Death-ligand 1 Expression in Upper Tract Urothelial Carcinoma. European Urology Focus, 2017, 3, 502-509.	1.6	25
237	Reply to Filippo Alongi, Rosario Mazzola, Dario Aiello and Matteo Salgarello's Letter to the Editor re: Re: Daniel E. Spratt, Hebert A. Vargas, Zachary S. Zumsteg, et al. Patterns of Lymph Node Failure after Dose-escalated Radiotherapy: Implications for Extended Pelvic Lymph Node Coverage. Eur Urol 2017;71:37â€“43. A Step Forward in the Era of Functional Imaging?. European Urology. 2017. 71. e123-e124.	0.9	0
238	Pan-Cancer Analysis of Genomic Sequencing Among the Elderly. International Journal of Radiation Oncology Biology Physics, 2017, 98, 726-732.	0.4	11
239	Challenges and opportunities in primary CNS lymphoma: A systematic review. Radiotherapy and Oncology, 2017, 122, 352-361.	0.3	38
240	Anatomical patterns of recurrence following biochemical relapse after postâ€“prostatectomy salvage radiation therapy: a multiâ€“institutional study. BJU International, 2017, 120, 351-357.	1.3	10
241	Vessel-sparing Radiotherapy for Localized Prostate Cancer to Preserve Erectile Function: A Single-arm Phase 2 Trial. European Urology, 2017, 72, 617-624.	0.9	50
242	Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy. JAMA Oncology, 2017, 3, 1663.	3.4	219
243	Unification of favourable intermediateâ€“, unfavourable intermediateâ€“, and very highâ€“risk stratification criteria for prostate cancer. BJU International, 2017, 120, E87-E95.	1.3	34
244	Breast and Prostate Cancer: Lessons to Be Shared. International Journal of Radiation Oncology Biology Physics, 2017, 98, 263-268.	0.4	3
245	Repeatability of [68Ga]DKFZ11-PSMA PET Scans for Detecting Prostate-specific Membrane Antigen-positive Prostate Cancer. Molecular Imaging and Biology, 2017, 19, 944-951.	1.3	7
246	Comparison of joint modeling and landmarking for dynamic prediction under an illnessâ€“death model. Biometrical Journal, 2017, 59, 1277-1300.	0.6	34
247	External beam radiation therapy with or without low-dose-rate brachytherapy: Analysis of favorable and unfavorable intermediate-risk prostate cancer patients. Brachytherapy, 2017, 16, 782-789.	0.2	7
248	Adjuvant Versus Early Salvage Radiation Therapy Following Radical Prostatectomy for Men with Localized Prostate Cancer. Current Urology Reports, 2017, 18, 55.	1.0	15
249	Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy Specimens. European Urology, 2017, 72, 845-852.	0.9	79
250	Low rates of androgen deprivation therapy use with salvage radiation therapy in patients with prostate cancer after radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 542.e25-542.e32.	0.8	6
251	National Trends and Predictors of Androgen Deprivation Therapy Use in Low-Risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 98, 338-343.	0.4	9
252	Editorial Comment. Journal of Urology, 2017, 197, 1075-1075.	0.2	0

#	ARTICLE	IF	CITATIONS
253	Genomic-adjusted radiation dose. <i>Lancet Oncology</i> , The, 2017, 18, e127.	5.1	5
254	To ProtecT Our Patients With Prostate Cancer. <i>JAMA Oncology</i> , 2017, 3, 1461.	3.4	2
255	Predictors of multidomain decline in health-related quality of life after stereotactic body radiation therapy (SBRT) for prostate cancer. <i>Cancer</i> , 2017, 123, 1635-1642.	2.0	14
256	Anatomic and functional imaging in the diagnosis of spine metastases and response assessment after spine radiosurgery. <i>Neurosurgical Focus</i> , 2017, 42, E5.	1.0	19
257	Modified risk stratification grouping using standard clinical and biopsy information for patients undergoing radical prostatectomy: Results from SEARCH. <i>Prostate</i> , 2017, 77, 1592-1600.	1.2	8
258	TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup. <i>Clinical Cancer Research</i> , 2017, 23, 7072-7083.	3.2	87
259	Beyond the androgen receptor II: New approaches to understanding and treating metastatic prostate cancer; Report from the 2017 Coffey-Holden Prostate Cancer Academy Meeting. <i>Prostate</i> , 2017, 77, 1478-1488.	1.2	7
260	Androgen receptor as a mediator and biomarker of radioresistance in triple-negative breast cancer. <i>Npj Breast Cancer</i> , 2017, 3, 29.	2.3	45
261	Convergence of Genomic Instability and SCHLAP1 : Weathering the Storm of Intraductal Carcinoma of the Prostate. <i>European Urology</i> , 2017, 72, 675-676.	0.9	2
262	Rare Presentation of Metastatic Cystic Trophoblastic Tumor in a Patient Without Prior Chemotherapy. <i>Urology Case Reports</i> , 2017, 13, 154-157.	0.1	4
263	An integrated multidisciplinary algorithm for the management of spinal metastases: an International Spine Oncology Consortium report. <i>Lancet Oncology</i> , The, 2017, 18, e720-e730.	5.1	220
264	Convergence of immunotherapy, radiotherapy and prostate cancer: challenges and opportunities. <i>Immunotherapy</i> , 2017, 9, 695-699.	1.0	0
265	American Brachytherapy Society Task Group Report: Combination of brachytherapy and external beam radiation for high-risk prostate cancer. <i>Brachytherapy</i> , 2017, 16, 1-12.	0.2	69
266	Number of Unfavorable Intermediate-Risk Factors Predicts Pathologic Upstaging and Prostate Cancer-Specific Mortality Following Radical Prostatectomy: Results From the SEARCH Database. <i>Prostate</i> , 2017, 77, 154-163.	1.2	22
267	Patterns of Lymph Node Failure after Dose-escalated Radiotherapy: Implications for Extended Pelvic Lymph Node Coverage. <i>European Urology</i> , 2017, 71, 37-43.	0.9	64
268	Very Early Salvage Radiotherapy Improves Distant Metastasis-Free Survival. <i>Journal of Urology</i> , 2017, 197, 662-668.	0.2	76
269	Individual Patient-Level Meta-Analysis of the Performance of the Decipher Genomic Classifier in High-Risk Men After Prostatectomy to Predict Development of Metastatic Disease. <i>Journal of Clinical Oncology</i> , 2017, 35, 1991-1998.	0.8	176
270	Independent surgical validation of the new prostate cancer grade grouping system. <i>BJU International</i> , 2016, 118, 763-769.	1.3	48

#	ARTICLE	IF	CITATIONS
271	Racial/Ethnic Disparities in Genomic Sequencing. <i>JAMA Oncology</i> , 2016, 2, 1070.	3.4	250
272	Comparing Two Multifraction Spine Radiotherapy Regimens: Are They Really Equivalent?. <i>Journal of Clinical Oncology</i> , 2016, 34, 2677-2677.	0.8	1
273	Long-term outcomes of dose-escalated intensity modulated radiation therapy alone without androgen deprivation therapy for patients with intermediate and high-risk prostate cancer. <i>Advances in Radiation Oncology</i> , 2016, 1, 300-309.	0.6	5
274	Salvage Radiotherapy After Prostatectomy: Two Sides of the Coin. <i>European Urology</i> , 2016, 70, 758-759.	0.9	4
275	Early magnetic resonance imaging biomarkers to predict local control after high dose stereotactic body radiotherapy for patients with sarcoma spine metastases. <i>Spine Journal</i> , 2016, 16, 291-298.	0.6	32
276	Vessel-sparing radiation and functional anatomy-based preservation for erectile function after prostate radiotherapy. <i>Lancet Oncology</i> , The, 2016, 17, e198-e208.	5.1	54
277	Multinational Prospective Study of Patient-Reported Outcomes After Prostate Radiation Therapy: Detailed Assessment of Rectal Bleeding. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 770-777.	0.4	11
278	Effect of the Maximum Dose on White Matter Fiber Bundles Using Longitudinal Diffusion Tensor Imaging. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 696-705.	0.4	29
279	Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis. <i>Lancet Oncology</i> , The, 2016, 17, 1612-1620.	5.1	182
280	Risk Stratification System and Pattern of Relapse in Patients Treated with Adjuvant Radiotherapy after Radical Prostatectomy. <i>Tumori</i> , 2016, 102, 323-329.	0.6	1
281	The Role of Transurethral Resection in Trimodal Therapy for Muscle-Invasive Bladder Cancer. <i>Bladder Cancer</i> , 2016, 2, 381-394.	0.2	15
282	Translational and clinical implications of the genetic landscape of prostate cancer. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 597-610.	12.5	63
283	Individual Patient Data Analysis of Randomized Clinical Trials: Impact of Black Race on Castration-resistant Prostate Cancer Outcomes. <i>European Urology Focus</i> , 2016, 2, 532-539.	1.6	23
284	Applying <sup>89</sup> Zr-Transferrin To Study the Pharmacology of Inhibitors to BET Bromodomain Containing Proteins. <i>Molecular Pharmaceutics</i> , 2016, 13, 683-688.	2.3	12
285	Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer. <i>JAMA Oncology</i> , 2016, 2, 471.	3.4	46
286	ACR Practice Parameter for the Performance of Therapy With Unsealed Radiopharmaceutical Sources. <i>Clinical Nuclear Medicine</i> , 2016, 41, 106-117.	0.7	4
287	Prognostic Value of Percent Gleason Grade 4 at Prostate Biopsy in Predicting Prostatectomy Pathology and Recurrence. <i>Journal of Urology</i> , 2016, 196, 405-411.	0.2	89
288	Targeting of radiolabeled J591 antibody to PSMA-expressing tumors: optimization of imaging and therapy based on non-linear compartmental modeling. <i>EJNMMI Research</i> , 2016, 6, 7.	1.1	32

#	ARTICLE	IF	CITATIONS
289	Stereotactic body radiotherapy for metastatic spinal sarcoma: a detailed patterns-of-failure study. <i>Journal of Neurosurgery: Spine</i> , 2016, 25, 52-58.	0.9	31
290	The Influence of Diabetes Mellitus and Metformin on Distant Metastases in Oropharyngeal Cancer: A Multicenter Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 523-531.	0.4	16
291	Recurrence Patterns and Second Primary Lung Cancers After Stereotactic Body Radiation Therapy for Early-Stage Non-Small-Cell Lung Cancer: Implications for Surveillance. <i>Clinical Lung Cancer</i> , 2016, 17, 177-183.e2.	1.1	57
292	Spine Radiosurgery in the Management of Renal Cell Carcinoma Metastases. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 801-809.	2.3	15
293	Disparities in Castration-Resistant Prostate Cancer Trials. <i>Journal of Clinical Oncology</i> , 2015, 33, 1101-1103.	0.8	43
294	Anatomical Patterns of Recurrence Following Biochemical Relapse in the Dose Escalation Era of External Beam Radiotherapy for Prostate Cancer. <i>Journal of Urology</i> , 2015, 194, 1624-1630.	0.2	93
295	PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer. <i>Science Translational Medicine</i> , 2015, 7, 283ra51.	5.8	276
296	Androgen Receptor Upregulation Mediates Radioresistance after Ionizing Radiation. <i>Cancer Research</i> , 2015, 75, 4688-4696.	0.4	105
297	Predictors of castration-resistant prostate cancer after dose-escalated external beam radiotherapy. <i>Prostate</i> , 2015, 75, 175-182.	1.2	11
298	The Natural History and Predictors of Outcome Following Biochemical Relapse in the Dose Escalation Era for Prostate Cancer Patients Undergoing Definitive External Beam Radiotherapy. <i>European Urology</i> , 2015, 67, 1009-1016.	0.9	147
299	Annotating STEAP1 Regulation in Prostate Cancer with 89Zr Immuno-PET. <i>Journal of Nuclear Medicine</i> , 2014, 55, 2045-2049.	2.8	25
300	Utility of FDG-PET in clinical neuroendocrine prostate cancer. <i>Prostate</i> , 2014, 74, 1153-1159.	1.2	55
301	Radiation Therapy in the Treatment of Minor Salivary Gland Tumors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2014, 37, 492-497.	0.6	18
302	Image-guided Radiation Therapy for Liver Tumors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2014, 37, 561-567.	0.6	6
303	Temporal relationship of post-operative radiotherapy with temozolomide and oncologic outcome for glioblastoma. <i>Journal of Neuro-Oncology</i> , 2014, 116, 357-363.	1.4	39
304	Efficacy of Skin-Directed Therapy for Cutaneous Metastases From Advanced Cancer: A Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2014, 32, 3144-3155.	0.8	131
305	Failure Patterns After Hemithoracic Pleural Intensity Modulated Radiation Therapy for Malignant Pleural Mesothelioma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 394-401.	0.4	55
306	Comparison of high-dose (86.4%G) IMRT vs combined brachytherapy plus IMRT for intermediate-risk prostate cancer. <i>BJU International</i> , 2014, 114, 360-367.	1.3	125

#	ARTICLE	IF	CITATIONS
307	The relative prognostic utility of standardized uptake value, gross tumor volume, and metabolic tumor volume in oropharyngeal cancer patients treated with platinum based concurrent chemoradiation with a pre-treatment [18F] fluorodeoxyglucose positron emission tomography scan. <i>Oral Oncology</i> , 2014, 50, 802-808.	0.8	34
308	Dose to the inferior pharyngeal constrictor predicts prolonged gastrostomy tube dependence with concurrent intensity-modulated radiation therapy and chemotherapy for locally-advanced head and neck cancer. <i>Radiotherapy and Oncology</i> , 2014, 110, 435-440.	0.3	45
309	A Prospective Pilot Study of <sup>89</sup> Zr-J591/Prostate Specific Membrane Antigen Positron Emission Tomography in Men with Localized Prostate Cancer Undergoing Radical Prostatectomy. <i>Journal of Urology</i> , 2014, 191, 1439-1445.	0.2	73
310	Impact of Dose to the Bladder Trigone on Long-Term Urinary Function After High-Dose Intensity Modulated Radiation Therapy for Localized Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 339-344.	0.4	122
311	Results of photon radiotherapy for unresectable salivary gland tumors: is neutron radiotherapy's local control superior?. <i>Radiology and Oncology</i> , 2014, 48, 56-61.	0.6	30
312	Cabozantinib Resolves Bone Scans in Tumor-Naïve Mice Harboring Skeletal Injuries. <i>Molecular Imaging</i> , 2014, 13, 7290.2014.00026.	0.7	7
313	Temporary organ displacement coupled with image-guided, intensity-modulated radiotherapy for paraspinal tumors. <i>Radiation Oncology</i> , 2013, 8, 150.	1.2	8
314	Distant metastasis is a critical mode of failure for patients with localized major salivary gland tumors treated with surgery and radiation. <i>Journal of Radiation Oncology</i> , 2013, 2, 285-291.	0.7	3
315	A comparative dosimetric analysis of virtual stereotactic body radiotherapy to high-dose-rate monotherapy for intermediate-risk prostate cancer. <i>Brachytherapy</i> , 2013, 12, 428-433.	0.2	45
316	Prognostic Importance of Gleason 7 Disease Among Patients Treated With External Beam Radiation Therapy for Prostate Cancer: Results of a Detailed Biopsy Core Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, 1254-1261.	0.4	20
317	Point: There is a need for supplemental XRT with brachytherapy in the treatment of intermediate-risk prostate cancer patients. <i>Brachytherapy</i> , 2013, 12, 389-392.	0.2	8
318	A New Risk Classification System for Therapeutic Decision Making with Intermediate-risk Prostate Cancer Patients Undergoing Dose-escalated External-beam Radiation Therapy. <i>European Urology</i> , 2013, 64, 895-902.	0.9	334
319	Rebuttal to Dr. Stone. <i>Brachytherapy</i> , 2013, 12, 398-399.	0.2	0
320	Long-term Survival and Toxicity in Patients Treated With High-Dose Intensity Modulated Radiation Therapy for Localized Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, 686-692.	0.4	229
321	Reply to Leah Bensimon, Samy Suissa, and Laurent Azoulay's Letter to the Editor re: Daniel E. Spratt, Chi Zhang, Zachary S. Zumsteg, Xin Pei, Zhigang Zhang, Michael J. Zelefsky. Metformin and Prostate Cancer: Reduced Development of Castration-resistant Disease and Prostate Cancer Mortality. <i>Eur Urol</i> 2013;63:709-716. <i>European Urology</i> , 2013, 64, e29-e30.	0.9	2
322	Patterns and Predictors of Amelioration of Genitourinary Toxicity After High-dose Intensity-modulated Radiation Therapy for Localized Prostate Cancer: Implications for Defining Postradiotherapy Urinary Toxicity. <i>European Urology</i> , 2013, 64, 931-938.	0.9	38
323	Metformin and Prostate Cancer: Reduced Development of Castration-resistant Disease and Prostate Cancer Mortality. <i>European Urology</i> , 2013, 63, 709-716.	0.9	152
324	Short-term Androgen-Deprivation Therapy Improves Prostate Cancer-Specific Mortality in Intermediate-Risk Prostate Cancer Patients Undergoing Dose-Escalated External Beam Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, 1012-1017.	0.4	55

#	ARTICLE	IF	CITATIONS
325	Androgen Receptor Signaling Regulates DNA Repair in Prostate Cancers. <i>Cancer Discovery</i> , 2013, 3, 1245-1253.	7.7	421
326	Time Course and Predictors for Cancer-Related Fatigue in a Series of Oropharyngeal Cancer Patients Treated with Chemoradiation Therapy. <i>Oncologist</i> , 2012, 17, 569-576.	1.9	22
327	Current and emerging treatment options for nasopharyngeal carcinoma. <i>OncoTargets and Therapy</i> , 2012, 5, 297.	1.0	32
328	International Spine Radiosurgery Consortium Consensus Guidelines for Target Volume Definition in Spinal Stereotactic Radiosurgery. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, e597-e605.	0.4	457
329	Targeting the Mechanisms of Resistance to Chemotherapy and Radiotherapy with the Cancer Stem Cell Hypothesis. <i>Journal of Oncology</i> , 2011, 2011, 1-13.	0.6	191
330	Locked-in: Listening to Save a Life. <i>Academic Medicine</i> , 2010, 85, 62.	0.8	0
331	Impact of FDG PET/CT on Delineation of the Gross Tumor Volume for Radiation Planning in Non-Small-Cell Lung Cancer. <i>Clinical Nuclear Medicine</i> , 2010, 35, 237-243.	0.7	25
332	An Automated Algorithm to Improve the Precision of Basilar Artery Diameter Measurements Before and After Subarachnoid Hemorrhage-Induced Vasospasm in an Animal Model. <i>Neurosurgery</i> , 2010, 66, 137-143.	0.6	1
333	Targeted Nanoparticles That Deliver a Sustained, Specific Release of Paclitaxel to Irradiated Tumors. <i>Cancer Research</i> , 2010, 70, 4550-4559.	0.4	136
334	Development and validation of a multivariable prognostic model in de novo metastatic castrate sensitive prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 0, .	2.0	4